The Phoenux companies are pharmaceutical innovation leaders united by a common goal: to make a major positive impact on the lives of people with innovative drugs for the debilitating diseases. We are specializing on drugs targeting medical indications of the central nervous system, mainly in the therapeutic areas of:
• Opioid substitution therapy
• Psychiatry, targeting Borderline Personality Disorder
The companies seek to target debilitating medical problems by identifying and developing the best possible therapeutic intervention through break through innovations.
Our core team has developed relevant IP. In our search to enhance our in-house competence we have collaborated with universities, research institutions, and private companies to find, develop and commercialize products.
Together with new partners the Phoenux group seeks to make a difference to improve in the lives of the patients opening new large market opportunities.
Phoenux group has developed;
• A non-generic non-abuse medication for the drug substitution market and brought it to phase IIB, including developing its very own galenical formulation.
• A worldwide patent for one other medication; Buprenorphine for Borderline illness has been granted in Europe and the US.
Regarding both projects we are interested to license or sell the IP as a whole or per country.
Clients in focus...